Literature DB >> 15550443

Role of the endocannabinoid system in the development of tolerance to alcohol.

Balapal S Basavarajappa1, Basalingappa L Hungund.   

Abstract

The present review evaluates the evidence that the endocannabinoid system plays in the development of tolerance to alcohol. The identification of a G-protein-coupled receptor, namely, the cannabinoid receptor (CB(1) receptor), which was activated by Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the major psychoactive component of marijuana, led to the discovery of endogenous cannabinoid agonists. Until now, four fatty acid derivatives identified to be arachidonylethanolamide (AEA), 2-arachidonylglycerol (2-AG), 2-arachidonylglycerol ether (noladin ether) and virodhamine have been isolated from both nervous and peripheral tissues. Both AEA and 2-AG have been shown to mimic the pharmacological and behavioural effects of Delta(9)-THC. The role of the endocannabinoid system in the development of tolerance to alcohol was not known until recently. Recent studies from our laboratory have implicated for the first time a role for the endocannabinoid system in development of tolerance to alcohol. Chronic alcohol treatment has been shown to down-regulate CB(1) receptors and its signal transduction. The observed downregulation of CB(1) receptor function results from the persistent stimulation of the receptors by AEA and 2-AG, the synthesis of which has been shown to be increased by chronic alcohol treatment. The enhanced formation of endocannabinoids may subsequently influence the release of neurotransmitters. It was found that the DBA/2 mice, known to avoid alcohol intake, have significantly reduced CB(1) receptor function in the brain, consistent with other studies in which the CB(1) receptor antagonist SR 141716A has been shown to block voluntary alcohol intake in rodents. Similarly, activation of the CB(1) receptor system promoted alcohol craving, suggesting a role for the CB(1) receptor gene in excessive alcohol drinking behaviour and development of alcoholism. Ongoing investigations may lead to a better understanding of the mechanisms underlying the development of tolerance to alcohol and to develop therapeutic strategies to treat alcoholism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550443     DOI: 10.1093/alcalc/agh111

Source DB:  PubMed          Journal:  Alcohol Alcohol        ISSN: 0735-0414            Impact factor:   2.826


  21 in total

Review 1.  Glutamate transporter 1: target for the treatment of alcohol dependence.

Authors:  P S S Rao; Y Sari
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Selective breeding for high alcohol preference is associated with increased sensitivity to cannabinoid reward within the nucleus accumbens shell.

Authors:  Sheketha R Hauser; Simon N Katner; Robert A Waeiss; William A Truitt; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Pharmacol Biochem Behav       Date:  2020-07-23       Impact factor: 3.533

Review 3.  The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.

Authors:  Giancarlo Colombo; Alessandro Orrù; Paola Lai; Claudia Cabras; Paola Maccioni; Marina Rubio; Gian Luigi Gessa; Mauro A M Carai
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

Review 4.  The endocannabinoid system in brain reward processes.

Authors:  M Solinas; S R Goldberg; D Piomelli
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

5.  Effects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference.

Authors:  Melanie M Pina; Christopher L Cunningham
Journal:  Alcohol       Date:  2014-05-21       Impact factor: 2.405

6.  Involvement of 2-arachidonoyl glycerol in the increased consumption of and preference for ethanol of mice treated with neurotoxic doses of methamphetamine.

Authors:  M D Gutierrez-Lopez; N Llopis; S Feng; D A Barrett; E O'Shea; M I Colado
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 7.  CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity.

Authors:  Emmanuel S Onaivi; Hiroki Ishiguro; Shanzhi Gu; Qing-Rong Liu
Journal:  J Psychopharmacol       Date:  2011-03-29       Impact factor: 4.153

8.  Ethanol-induced alterations in endocannabinoids and relevant neurotransmitters in the nucleus accumbens of fatty acid amide hydrolase knockout mice.

Authors:  Francisco J Pavón; Antonia Serrano; David G Stouffer; Ilham Polis; Marisa Roberto; Benjamin F Cravatt; Rémi Martin-Fardon; Fernando Rodríguez de Fonseca; Loren H Parsons
Journal:  Addict Biol       Date:  2018-11-13       Impact factor: 4.280

9.  Drunken Membranes: Short-Chain Alcohols Alter Fusion of Liposomes to Planar Lipid Bilayers.

Authors:  Jason Paxman; Brady Hunt; David Hallan; Samuel R Zarbock; Dixon J Woodbury
Journal:  Biophys J       Date:  2017-01-10       Impact factor: 4.033

10.  Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol.

Authors:  Torbjörn U C Järbe; Chen Li; Subramanian K Vadivel; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2009-11-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.